Latest Content

FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.

Yesne Alici, MD, of Memorial Sloan Kettering Cancer Center discusses key delirium screening, patient capacity, and bioethics in oncology nursing care.

A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.

FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.

Erik Bengtsen, MD, of Memorial Sloan Kettering Cancer Center, discusses psilocybin research, demoralization, and psychopharmacology in oncology care.

Ramy Sedhom, MD, of Penn Medicine Princeton Health discusses blending palliative care with psycho-oncology to treat patient distress in oncology care.

FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.

At WCLC 2026, Kaitlyn Gregory details key oncology nursing insights into exercise, caregiver stress, screening models, and APP-led supportive care.

FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.

Gigi Jameel, APRN, discusses supportive care interventions, ADT toxicity management, and team collaboration in prostate cancer care.

Patients often use AI to read test results, but AI can misinterpret data and cause panic. Learn why human context remains critical.

Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.